bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S4 from Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer
Authors: Vathiotis Ioannis A. , Moutafi Myrto K. , Divakar Prajan , Aung Thazin Nwe , Qing Tao , Fernandez Aileen , Yaghoobi Vesal , El-Abed Sarra , Wang Yingbo , Guillaume Sebastien , Nuciforo Paolo , Huober Jens , Di Cosimo Serena , Kim Sung-Bae , Harbeck Nadia , Gomez Henry , Shafi Saba , Syrigos Konstantinos N. , Fountzilas George , Sotiriou Christos , Pusztai Lajos , Warren Sarah , Rimm David L.
Published: April 2023

Scatter plots showing the correlation between digital counts of a-SMA in leukocyte, macrophage (A) and stroma compartments (B). Scatter plots showing the correlation between digital counts of a-SMA in stroma, CTLA-4 in leukocyte (C) and CD45 in leukocyte compartments.
Supplementary Figure 9 from Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies
Authors: Lee Jaewon J. , Bernard Vincent , Semaan Alexander , Monberg Maria E. , Huang Jonathan , Stephens Bret M. , Lin Daniel , Rajapakshe Kimal I. , Weston Brian R. , Bhutani Manoop S. , Haymaker Cara L. , Bernatchez Chantale , Taniguchi Cullen M. , Maitra Anirban , Guerrero Paola A.
Published: April 2023

Supplementary Figure
Supplementary Data from Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
Authors: Brown Landon C. , Halabi Susan , Schonhoft Joseph D. , Yang Qian , Luo Jun , Nanus David M. , Giannakakou Paraskevi , Szmulewitz Russell Z. , Danila Daniel C. , Barnett Ethan S. , Carbone Emily A. , Zhao Jimmy L. , Healy Patrick , Anand Monika , Gill Audrey , Jendrisak Adam , Berry William R. , Gupta Santosh , Gregory Simon G. , Wenstrup Richard , Antonarakis Emmanuel S. , George Daniel J. , Scher Howard I. , Armstrong Andrew J.
Published: April 2023

Supplemental methods, figures, tables
Supplementary Figure 1 from Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies
Authors: Lee Jaewon J. , Bernard Vincent , Semaan Alexander , Monberg Maria E. , Huang Jonathan , Stephens Bret M. , Lin Daniel , Rajapakshe Kimal I. , Weston Brian R. , Bhutani Manoop S. , Haymaker Cara L. , Bernatchez Chantale , Taniguchi Cullen M. , Maitra Anirban , Guerrero Paola A.
Published: April 2023

figure
Figure S1, Figure S2, Figure S3, Figure S4 from Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
Authors: Kim Seung Tae , Smith Simon A. , Mortimer Peter , Loembé Arsene-Bienvenu , Cho Heejin , Kim Kyoung-Mee , Smith Claire , Willis Sophie , Irurzun-Arana Itziar , Berges Alienor , Hong Jung Yong , Park Se Hoon , Park Joon Oh , Park Young Suk , Lim Ho Yeong , Kang Won Ki , Kozarewa Iwanka , Pierce Andrew J. , Dean Emma , Lee Jeeyun
Published: April 2023

Supplementary Figure 1. Single dose ceralasertib PK. PK from patients in cohorts 1 to 4 was in line with the PK model predictions (shadowed area) built with data from other studies. Supplementary Figure 2. ATM protein expression by IHC in patients with melanoma. Supplementary Figure 3. ctDNA clearance of mutant alleles from a responder to ceralasertib+paclitaxel; example 1. ctDNA was sequenced at baseline, day 61 and day 403. Re-staging scans were performed at day 63, day 117, intermediate days at approximate 8 week intervals (not shown) and day 426 (at the time of PD). The stream plot shows rapid clearance of the mutant alleles in line with RECIST v1.1 response. Supplementary Figure 4. CtDNA clearance of mutant alleles from a responder to ceralasertib+paclitaxel; example 2. ctDNA was sequenced at baseline, day 24, day 52 and day 241. Re-staging scans were performed at day 46, day 98, intermediate days at approximate 8 week intervals (not shown) and day 235. The stream plot shows rapid clearance of the mutant alleles prior to the day of the first re-staging scan which showed a RECIST v1.1 response.
Table S6 from The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients
Authors: Zheng Bo , Liu Xiao-Long , Fan Rong , Bai Jian , Wen Hao , Du Lu-Tao , Jiang Guo-Qing , Wang Chun-Ying , Fan Xiao-Tang , Ye Yi-Nong , Qian Yun-Song , Wang Ying-Chao , Liu Gao-Jing , Deng Guo-Hong , Shen Feng , Hu He-Ping , Wang Hui , Zhang Qing-Zheng , Ru Lan-Lan , Zhang Jing , Gao Yan-Hang , Xia Jie , Yan Hua-Dong , Liang Min-Feng , Yu Yan-Long , Sun Fu-Ming , Gao Yu-Jing , Sun Jian , Zhong Chun-Xiu , Wang Yin , Kong Fei , Chen Jin-Ming , Zheng Dan , Yang Yuan , Wang Chuan-Xin , Wu Lin , Hou Jin-Lin , Liu Jing-Feng , Wang Hong-Yang , Chen Lei
Published: April 2023

Table S6
Supplementary Data from Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome
Authors: Otvos Balint , Alban Tyler J. , Grabowski Matthew M. , Bayik Defne , Mulkearns-Hubert Erin E. , Radivoyevitch Tomas , Rabljenovic Anja , Johnson Sarah , Androjna Charlie , Mohammadi Alireza M. , Barnett Gene H. , Ahluwalia Manmeet S. , Vogelbaum Michael A. , Fecci Peter E. , Lathia Justin D.
Published: April 2023

Supplementary Figures 1-18
Supplemental Methods 2 from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes
Authors: Chang Jason C. , Offin Michael , Falcon Christina , Brown David , Houck-Loomis Brian R. , Meng Fanli , Rudneva Vasilisa A. , Won Helen H. , Amir Sharon , Montecalvo Joseph , Desmeules Patrice , Kadota Kyuichi , Adusumilli Prasad S. , Rusch Valerie W. , Teed Sarah , Sabari Joshua K. , Benayed Ryma , Nafa Khedoudja , Borsu Laetitia , Li Bob T. , Schram Alison M. , Arcila Maria E. , Travis William D. , Ladanyi Marc , Drilon Alexander , Rekhtman Natasha
Published: April 2023

Supplemental Methods 2
Supplemental Figure 2 from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes
Authors: Chang Jason C. , Offin Michael , Falcon Christina , Brown David , Houck-Loomis Brian R. , Meng Fanli , Rudneva Vasilisa A. , Won Helen H. , Amir Sharon , Montecalvo Joseph , Desmeules Patrice , Kadota Kyuichi , Adusumilli Prasad S. , Rusch Valerie W. , Teed Sarah , Sabari Joshua K. , Benayed Ryma , Nafa Khedoudja , Borsu Laetitia , Li Bob T. , Schram Alison M. , Arcila Maria E. , Travis William D. , Ladanyi Marc , Drilon Alexander , Rekhtman Natasha
Published: April 2023

Supplemental Figure 2. Detailed graphical visualizations of the F11R-NRG2 fusion.
Supplementary Data from Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment
Authors: Vardaki Ioulia , Corn Paul , Gentile Emanuela , Song Jian H. , Madan Namrata , Hoang Anh , Parikh Nila , Guerra Leah , Lee Yu-Chen , Lin Song-Chang , Yu Guoyu , Santos Elmer , Melancon Marites P. , Troncoso Patricia , Navone Nora , Gallick Gary E. , Efstathiou Eleni , Subudhi Sumit K. , Lin Sue-Hwa , Logothetis Christopher J. , Panaretakis Theocharis
Published: April 2023

Supplementary Figures
Supplementary Data from Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib
Authors: Brieghel Christian , Aarup Kathrine , Torp Mathias H. , Andersen Michael A. , Yde Christina W. , Tian Xin , Wiestner Adrian , Ahn Inhye E. , Niemann Carsten U.
Published: April 2023

Supplementary tables S1, S2 and supplementary figures S1-S6
Table S5 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Authors: Monaco Kelli-Ann , Delach Scott , Yuan Jing , Mishina Yuji , Fordjour Paul , Labrot Emma , McKay Daniel , Guo Ribo , Higgins Stacy , Wang Hui Qin , Liang Jinsheng , Bui Karen , Green John , Aspesi Peter , Ambrose Jessi , Mapa Felipa , Griner Lesley , Jaskelioff Mariela , Fuller John , Crawford Kenneth , Pardee Gwynn , Widger Stephania , Hammerman Peter S. , Engelman Jeffrey A. , Stuart Darrin D. , Cooke Vesselina G. , Caponigro Giordano
Published: April 2023

p-ERK MSD results in RAS mutant cells ectopically expressed ARAF variants
Supplementary Data from Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer
Authors: Kazi Aslamuzzaman , Chen Liwei , Xiang Shengyan , Vangipurapu Rajanikanth , Yang Hua , Beato Francisca , Fang Bin , Williams Terence M. , Husain Kazim , Underwood Patrick , Fleming Jason B. , Malafa Mokenge , Welsh Eric A. , Koomen John , Trevino José , Sebti Saïd M.
Published: April 2023

Supplementary Table 3
Table S1 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Authors: Monaco Kelli-Ann , Delach Scott , Yuan Jing , Mishina Yuji , Fordjour Paul , Labrot Emma , McKay Daniel , Guo Ribo , Higgins Stacy , Wang Hui Qin , Liang Jinsheng , Bui Karen , Green John , Aspesi Peter , Ambrose Jessi , Mapa Felipa , Griner Lesley , Jaskelioff Mariela , Fuller John , Crawford Kenneth , Pardee Gwynn , Widger Stephania , Hammerman Peter S. , Engelman Jeffrey A. , Stuart Darrin D. , Cooke Vesselina G. , Caponigro Giordano
Published: April 2023

Biochemical activity of LXH254
Supplementary Tables from Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia
Authors: Hunter Anthony M. , Newman Hannah , Dezern Amy E. , Steensma David P. , Niyongere Sandrine , Roboz Gail J. , Mo Qianxing , Chan Onyee , Gerds Aaron , Sallman David A. , Dominguez-Viqueira William , Letson Christopher , Balasis Maria E. , Ball Markus , Kruer Traci , Zhang Hailing , Lancet Jeffrey E. , List Alan F. , Sekeres Mikkael A. , Komrokji Rami S. , Padron Eric
Published: April 2023

Supplementary Table S1 details the IWG response criteria for MDS/MPNs. Supplementary Table S2 summarizes grade 3 and 4 treatment-emergent toxicities. Supplementary Table S3 summarizes all recorded adverse events. Supplementary Table S4 summarizes the reasons for treatment discontinuation. Supplementary Table S5 details the baseline characteristics of patients from which patient-derived xenograft mice were generated.
Supplementary Figure S7 from Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia
Authors: Hunter Anthony M. , Newman Hannah , Dezern Amy E. , Steensma David P. , Niyongere Sandrine , Roboz Gail J. , Mo Qianxing , Chan Onyee , Gerds Aaron , Sallman David A. , Dominguez-Viqueira William , Letson Christopher , Balasis Maria E. , Ball Markus , Kruer Traci , Zhang Hailing , Lancet Jeffrey E. , List Alan F. , Sekeres Mikkael A. , Komrokji Rami S. , Padron Eric
Published: April 2023

Supplementary Figure S7 depicts a receiver operating characteristic curve evaluating the performance of patient-derived xenograft mouse survival as a predictor of response.
Supplementary Figure S5 from Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia
Authors: Hunter Anthony M. , Newman Hannah , Dezern Amy E. , Steensma David P. , Niyongere Sandrine , Roboz Gail J. , Mo Qianxing , Chan Onyee , Gerds Aaron , Sallman David A. , Dominguez-Viqueira William , Letson Christopher , Balasis Maria E. , Ball Markus , Kruer Traci , Zhang Hailing , Lancet Jeffrey E. , List Alan F. , Sekeres Mikkael A. , Komrokji Rami S. , Padron Eric
Published: April 2023

Supplementary Figure S5 depicts endpoint assessments compared between vehicle-treated and ruxolitinib-treated patient-derived xenograft mice.
Supplementary Figure 7 from Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas
Authors: Mudianto Tenny , Campbell Katie M. , Webb Jason , Zolkind Paul , Skidmore Zachary L. , Riley Rachel , Barnell Erica K. , Ozgenc Ibrahim , Giri Tusar , Dunn Gavin P. , Adkins Douglas R. , Griffith Malachi , Egloff Ann Marie , Griffith Obi L. , Uppaluri Ravindra
Published: April 2023

Supplementary Figure 7
Supplementary Table 5 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model
Authors: Gordon Max J. , Kaempf Andy , Sitlinger Andrea , Shouse Geoffrey , Mei Matthew , Brander Danielle M. , Salous Tareq , Hill Brian T. , Alqahtani Hamood , Choi Michael , Churnetski Michael C. , Cohen Jonathon B. , Stephens Deborah M. , Siddiqi Tanya , Rivera Xavier , Persky Daniel , Wisniewski Paul , Patel Krish , Shadman Mazyar , Park Byung , Danilov Alexey V.
Published: April 2023

S Table 5
Supplementary Table 4 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model
Authors: Gordon Max J. , Kaempf Andy , Sitlinger Andrea , Shouse Geoffrey , Mei Matthew , Brander Danielle M. , Salous Tareq , Hill Brian T. , Alqahtani Hamood , Choi Michael , Churnetski Michael C. , Cohen Jonathon B. , Stephens Deborah M. , Siddiqi Tanya , Rivera Xavier , Persky Daniel , Wisniewski Paul , Patel Krish , Shadman Mazyar , Park Byung , Danilov Alexey V.
Published: April 2023

S Table 4
Supplementary Figure 1 from Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas
Authors: Mudianto Tenny , Campbell Katie M. , Webb Jason , Zolkind Paul , Skidmore Zachary L. , Riley Rachel , Barnell Erica K. , Ozgenc Ibrahim , Giri Tusar , Dunn Gavin P. , Adkins Douglas R. , Griffith Malachi , Egloff Ann Marie , Griffith Obi L. , Uppaluri Ravindra
Published: April 2023

Supplementary Figure 1
Supplementary Data Tables S1-S4 from Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors
Authors: Foster Corey C. , Fleming Gini F. , Karrison Theodore G. , Liao Chih-Yi , Desai Ami V. , Moroney John W. , Ratain Mark J. , Nanda Rita , Polite Blase N. , Hahn Olwen M. , O'Donnell Peter H. , Vokes Everett E. , Kindler Hedy L. , Hseu Robyn , Janisch Linda A. , Dai Julia , Hoffman Mark D. , Weichselbaum Ralph R. , Pitroda Sean P. , Chmura Steven J. , Luke Jason J.
Published: April 2023

Table S1 shows the included solid tumor histologies for enrolled patients. Table S2 shows at least possibly treatment-related grade 2 or greater adverse events among patients remaining on study for at least 3 months. Table S3 shows all adverse events among patients remaining on study for at least 3 months. Table S4 shows the proportion of patients receiving stereotactic body radiation therapy to all RECIST target lesions and all clinically or radiographically apparent metastases by response category.
Figure S4 from Regulation of OATP1B1 Function by Tyrosine Kinase–mediated Phosphorylation
Authors: Hayden Elizabeth R. , Chen Mingqing , Pasquariello Kyle Z. , Gibson Alice A. , Petti James J. , Shen Shichen , Qu Jun , Ong Su Sien , Chen Taosheng , Jin Yan , Uddin Muhammad Erfan , Huang Kevin M. , Paz Aviv , Sparreboom Alex , Hu Shuiying , Sprowl Jason A.
Published: April 2023

Assessment of LYN kinase expression, and function in the presence of various TKIs. (A) Detection of LYN protein expression in human hepatocyte and spleen lysates as determined by Western blot analysis. Prior to analysis, spleen (1:10) and liver (1:1) lysates were diluted. Protein expression of GAPDH was measured as a loading control. The image is a representative of 3 independent experiments. (B) LYN activity in the presence of various TKI concentrations (10-doses) was determined using a kinase assay. (C) Regression of LYN IC50 values of several TKIs and percent of LYN inhibition.
Table S1 from Spatial Mapping and Immunomodulatory Role of the OX40/OX40L Pathway in Human Non–Small Cell Lung Cancer
Authors: Porciuncula Angelo , Morgado Micaela , Gupta Richa , Syrigos Kostas , Meehan Robert , Zacharek Sima J. , Frederick Joshua P. , Schalper Kurt A.
Published: April 2023

Supplementary Table S1
Supplementary Data from Adjuvant Low-dose Statin Use after Radical Prostatectomy: The PRO-STAT Randomized Clinical Trial
Authors: Jeong In Gab , Lim Bumjin , Yun Sung-Cheol , Lim Ju Hyun , Hong Jun Hyuk , Kim Choung-Soo
Published: April 2023

Supplemental appendix
Supplemental Methods from Sulindac, a Nonselective NSAID, Reduces Breast Density in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors
Authors: Thompson Patricia A. , Huang Chuan , Yang Jie , Wertheim Betsy C. , Roe Denise , Zhang Xiaoyue , Ding Jie , Chalasani Pavani , Preece Christina , Martinez Jessica , Chow H.-H. Sherry , Stopeck Alison T.
Published: April 2023

Details on MRI Scanner information.
Supplementary Data from Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer
Authors: Steele Nina G. , Biffi Giulia , Kemp Samantha B. , Zhang Yaqing , Drouillard Donovan , Syu LiJyun , Hao Yuan , Oni Tobiloba E. , Brosnan Erin , Elyada Ela , Doshi Abhishek , Hansma Christa , Espinoza Carlos , Abbas Ahmed , The Stephanie , Irizarry-Negron Valerie , Halbrook Christopher J. , Franks Nicole E. , Hoffman Megan T. , Brown Kristee , Carpenter Eileen S. , Nwosu Zeribe C. , Johnson Craig , Lima Fatima , Anderson Michelle A. , Park Youngkyu , Crawford Howard C. , Lyssiotis Costas A. , Frankel Timothy L. , Rao Arvind , Bednar Filip , Dlugosz Andrzej A. , Preall Jonathan B. , Tuveson David A. , Allen Benjamin L. , Pasca di Magliano Marina
Published: April 2023

Supp Figure legends
Figure.S2 from Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma
Authors: Lone Waseem , Bouska Alyssa , Sharma Sunandini , Amador Catalina , Saumyaranjan Mallick , Herek Tyler A. , Heavican Tayla B. , Yu Jiayu , Lim Soon Thye , Ong Choon Kiat , Slack Graham W. , Savage Kerry J. , Rosenwald Andreas , Ott German , Cook James R. , Feldman Andrew L. , Rimsza Lisa M. , McKeithan Timothy W. , Greiner Timothy C. , Weisenburger Dennis D. , Melle Federica , Motta Giovanna , Pileri Stefano , Vose Julie M. , Chan Wing C. , Iqbal Javeed
Published: April 2023

Figure S2: Expression of lineage specific markers in Polarized CD4+ T cells from different biological donors A: Flow cytometry profiles displaying CXCR5 and PD-1 expression in CD4 T cells cultured with IL-21. B. Flow cytometry profiles displaying GATA3 and TBX21 expression in CD4 T cells cultured in TH1 or TH2 differentiation media.
Supplementary Figure S1 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
Authors: Subbiah Vivek , Gainor Justin F. , Oxnard Geoffrey R. , Tan Daniel S.W. , Owen Dwight H. , Cho Byoung Chul , Loong Herbert H. , McCoach Caroline E. , Weiss Jared , Kim Yu Jung , Bazhenova Lyudmila , Park Keunchil , Daga Haruko , Besse Benjamin , Gautschi Oliver , Rolfo Christian , Zhu Edward Y. , Kherani Jennifer F. , Huang Xin , Kang Suhyun , Drilon Alexander
Published: April 2023

LIBRETTO-001 Trial Profile
Table S6 from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Authors: Tayari Mina M. , Santos Helena G. Dos , Kwon Deukwoo , Bradley Terrence J. , Thomassen Amber , Chen Charles , Dinh Yvonne , Perez Aymee , Zelent Arthur , Morey Lluis , Cimmino Luisa , Shiekhattar Ramin , Swords Ronan T. , Watts Justin M.
Published: April 2023

Table S6
Table S4 from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Authors: Tayari Mina M. , Santos Helena G. Dos , Kwon Deukwoo , Bradley Terrence J. , Thomassen Amber , Chen Charles , Dinh Yvonne , Perez Aymee , Zelent Arthur , Morey Lluis , Cimmino Luisa , Shiekhattar Ramin , Swords Ronan T. , Watts Justin M.
Published: April 2023

Table S4
Table S3 from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Authors: Tayari Mina M. , Santos Helena G. Dos , Kwon Deukwoo , Bradley Terrence J. , Thomassen Amber , Chen Charles , Dinh Yvonne , Perez Aymee , Zelent Arthur , Morey Lluis , Cimmino Luisa , Shiekhattar Ramin , Swords Ronan T. , Watts Justin M.
Published: April 2023

Table S3
Supplemental Figure 1 from Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET
Authors: Werner Jan-Michael , Weller Johannes , Ceccon Garry , Schaub Christina , Tscherpel Caroline , Lohmann Philipp , Bauer Elena K. , Schäfer Niklas , Stoffels Gabriele , Baues Christian , Celik Eren , Marnitz Simone , Kabbasch Christoph , Gielen Gerrit H. , Fink Gereon R. , Langen Karl-Josef , Herrlinger Ulrich , Galldiks Norbert
Published: April 2023

Supplemental Figure 1 shows increase of time-to-peak supporting the diagnosis of pseudoprogression
Supplementary Methods from Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)
Authors: Roussos Torres Evanthia T. , Rafie Christine , Wang Chenguang , Lim David , Brufsky Adam , LoRusso Patricia , Eder Joseph Paul , Chung Vincent , Downs Melinda , Geare Molly , Piekarz Richard , Streicher Howard , Anforth Leslie , Rudek Michelle A. , Zhu Qingfeng , Besharati Sepideh , Cimino-Mathews Ashley , Anders Robert A. , Stearns Vered , Jaffee Elizabeth M. , Connolly Roisin M.
Published: April 2023

Supplementary methods
Figure S5 from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Authors: Tayari Mina M. , Santos Helena G. Dos , Kwon Deukwoo , Bradley Terrence J. , Thomassen Amber , Chen Charles , Dinh Yvonne , Perez Aymee , Zelent Arthur , Morey Lluis , Cimmino Luisa , Shiekhattar Ramin , Swords Ronan T. , Watts Justin M.
Published: April 2023

Figure S5. Gene expression induction of TCP-driven gene signature in patients treated with ATRA-TCP.
Supplementary Table S1 and S2 from First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody
Authors: Kist de Ruijter Laura , Hooiveld-Noeken Jahlisa S. , Giesen Danique , Lub-de Hooge Marjolijn N. , Kok Iris C. , Brouwers Adrienne H. , Elias Sjoerd G. , Nguyen Margaret T.L. , Lu Hong , Gietema Jourik A. , Jalving Mathilde , de Groot Derk J.A. , Vasiljeva Olga , de Vries Elisabeth G.E.
Published: April 2023

Supplementary Tables
Supplementary Figure 5 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Authors: Ali Aesha I. , Wang Minyu , von Scheidt Bianca , Dominguez Pilar M. , Harrison Aaron J. , Tantalo Daniela G.M. , Kang Jian , Oliver Amanda J. , Chan Jack D. , Du Xin , Bai Yuchen , Lee Belinda , Johnstone Ricky W. , Darcy Phillip K. , Kershaw Michael H. , Slaney Clare Y.
Published: April 2023

Supplementary Figure 5. Pano did not alter Her2 or H2-Db expression on Panc02-Her2 tumor cells in vivo and CARaMEL cells were detectable over 100 days in ACTIV+ Pano treated mice.
Supplementary Figure 4 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Authors: Ali Aesha I. , Wang Minyu , von Scheidt Bianca , Dominguez Pilar M. , Harrison Aaron J. , Tantalo Daniela G.M. , Kang Jian , Oliver Amanda J. , Chan Jack D. , Du Xin , Bai Yuchen , Lee Belinda , Johnstone Ricky W. , Darcy Phillip K. , Kershaw Michael H. , Slaney Clare Y.
Published: April 2023

Supplementary Figure 4. Pano did not enhance the cytotoxicity of CARaMEL cells nor oncolysis of VV-gp100.
Supplementary Figure 2 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Authors: Ali Aesha I. , Wang Minyu , von Scheidt Bianca , Dominguez Pilar M. , Harrison Aaron J. , Tantalo Daniela G.M. , Kang Jian , Oliver Amanda J. , Chan Jack D. , Du Xin , Bai Yuchen , Lee Belinda , Johnstone Ricky W. , Darcy Phillip K. , Kershaw Michael H. , Slaney Clare Y.
Published: April 2023

Supplementary Figure 2. Pancreatic cells are resistant to VV-gp100 oncolysis but sensitive to CAR T cell-mediated cytotoxicity.
Figure S5 from Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors
Authors: Chakraborty Goutam , Patail Nabeela Khan , Hirani Rahim , Nandakumar Subhiksha , Mazzu Ying Z. , Yoshikawa Yuki , Atiq Mohammad , Jehane Lina E. , Stopsack Konrad H. , Lee Gwo-Shu Mary , Abida Wassim , Morris Michael J. , Mucci Lorelei A. , Danila Daniel , Kantoff Philip W.
Published: April 2023

Figure S5
Supplementary Methods from Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care
Authors: Chakraborty Saptarshi , Ecker Brett L. , Seier Ken , Aveson Victoria G. , Balachandran Vinod P. , Drebin Jeffrey A. , D'Angelica Michael I. , Kingham T. Peter , Sigel Carlie S. , Soares Kevin C. , Vakiani Efsevia , Wei Alice C. , Chandwani Rohit , Gonen Mithat , Shen Ronglai , Jarnagin William R.
Published: April 2023

Supplementary Methods
Supplementary Legend from Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity
Authors: Sharma Ashwyn K. , de la Torre Jorge , IJzerman Nikki S. , Sutton Thomas L. , Zhao Beiqun , Khan Tahsin M. , Banerjee Sudeep , Cui Christina , Nguyen Vi , Alkhuziem Maha , Snaebjornsson Petur , van Boven Hester , Bruining Annemarie , Tang Chih-Min , Yoon Hyunho , De la Fuente Alexa , Kato Shumei , Patel Hitendra , Heinrich Michael C. , Corless Christopher L. , Horgan Santiago , Burgoyne Adam M. , Fanta Paul , Mesirov Jill P. , Blakely Andrew M. , Davis Jeremy L. , Mayo Skye C. , van Houdt Winan J. , Steeghs Neeltje , Sicklick Jason K.
Published: April 2023

Supplementary Legend
Supp FIgure 5 from Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care
Authors: Chakraborty Saptarshi , Ecker Brett L. , Seier Ken , Aveson Victoria G. , Balachandran Vinod P. , Drebin Jeffrey A. , D'Angelica Michael I. , Kingham T. Peter , Sigel Carlie S. , Soares Kevin C. , Vakiani Efsevia , Wei Alice C. , Chandwani Rohit , Gonen Mithat , Shen Ronglai , Jarnagin William R.
Published: April 2023

Supp FIgure
Supp FIgure 3 from Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care
Authors: Chakraborty Saptarshi , Ecker Brett L. , Seier Ken , Aveson Victoria G. , Balachandran Vinod P. , Drebin Jeffrey A. , D'Angelica Michael I. , Kingham T. Peter , Sigel Carlie S. , Soares Kevin C. , Vakiani Efsevia , Wei Alice C. , Chandwani Rohit , Gonen Mithat , Shen Ronglai , Jarnagin William R.
Published: April 2023

Supp FIgure
Supplementary Table 1 from Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E-Driven Papillary Thyroid Cancer Patients
Authors: Pappa Theodora , Ahmadi Sara , Marqusee Ellen , Johnson Hannah L. , Nehs Matthew A. , Cho Nancy L. , Barletta Justine A. , Lorch Jochen H. , Doherty Gerard M. , Lindeman Neal I. , Alexander Erik K. , Landa Iñigo
Published: April 2023

Comparison of clinical and pathological features of thyroid cancer patients with BRAF mutations only versus BRAF plus additional mutations.
Supplemental Figure 1 from Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E-Driven Papillary Thyroid Cancer Patients
Authors: Pappa Theodora , Ahmadi Sara , Marqusee Ellen , Johnson Hannah L. , Nehs Matthew A. , Cho Nancy L. , Barletta Justine A. , Lorch Jochen H. , Doherty Gerard M. , Lindeman Neal I. , Alexander Erik K. , Landa Iñigo
Published: April 2023

Comparison of minor allele frequencies between additional oncogenic mutations and BRAFV600E.
Supplementary Figure S8 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Authors: Kerbauy Lucila N. , Marin Nancy D. , Kaplan Mecit , Banerjee Pinaki P. , Berrien-Elliott Melissa M. , Becker-Hapak Michelle , Basar Rafet , Foster Mark , Garcia Melo Luciana , Neal Carly C. , McClain Ethan , Daher May , Nunez Cortes Ana Karen , Desai Sweta , Inng Lim Francesca Wei , Mendt Mayela Carolina , Schappe Timothy , Li Li , Shaim Hila , Shanley Mayra , Ensley Emily L. , Uprety Nadima , Wong Pamela , Liu Enli , Ang Sonny O. , Cai Rong , Nandivada Vandana , Mohanty Vakul , Miao Qi , Shen Yifei , Baran Natalia , Fowlkes Natalie W. , Chen Ken , Muniz-Feliciano Luis , Champlin Richard E. , Nieto Yago L. , Koch Joachim , Treder Martin , Fischer Wolfgang , Okamoto Oswaldo Keith , Shpall Elizabeth J. , Fehniger Todd A. , Rezvani Katayoun
Published: April 2023

Supplementary Fig. S8. AFM13 loaded and washed P+E CB-NK cells are safe without in vivo evidence of autonomous or dysregulated growth.
Supplementary Figure S7 from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Authors: Chu Carissa E. , Sjöström Martin , Egusa Emily A. , Gibb Ewan A. , Badura Michelle L. , Zhu Jun , Koshkin Vadim S. , Stohr Bradley A. , Meng Maxwell V. , Pruthi Raj S. , Friedlander Terence W. , Lotan Yair , Black Peter C. , Porten Sima P. , Feng Felix Y. , Chou Jonathan
Published: April 2023

(A) NECTIN4 surface protein expression in UMUC-14, 647V and HT-1376 cells. Gray denotes unstained control cells and red denotes NECTIN4-PE antibody stain. (B) Combined histograms of NECTIN4 surface protein expression in UMUC-14 (purple), 647V (green) and HT-1376 (blue) cells. (C) Western blot of NECTIN4 protein expression in whole cell lysates of UMUC-14, 647V and HT-1376 cells. (D) Phase-contrast brightfield microscopy of UMUC-14 and 647V bladder cancer cells. Scale bar = 200 mm. (E) EV dose-response assay in UMUC-14 (purple, basal), 647V (green, basal) and HT-1376 (blue, luminal) cells.
Supplementary figure legend 1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
Authors: Najjar Yana G. , McCurry Dustin , Lin Huang , Lin Yan , Zang Yan , Davar Diwakar , Karunamurthy Arivarasan , Drabick Joseph J. , Neves Rogerio I. , Butterfield Lisa H. , Ernstoff Marc S. , Puzanov Igor , Skitzki Joseph J. , Bordeaux Jennifer , Summit IlaSri B. , Bender Jehovana O. , Kim Ju Young , Chen Beiru , Sarikonda Ghanashyam , Pahuja Anil , Tsau Jennifer , Alfonso Zeni , Laing Christian , Pingpank James F. , Holtzman Matthew P. , Sander Cindy , Rose Amy , Zarour Hassane M. , Kirkwood John M. , Tarhini Ahmad A.
Published: April 2023

Representative gating strategy illustrating (A) CD4 and CD8 T cell identification (B) expression of ICOS on CD4 positive T cells (C) expression of PD-1 and Ki-67 within PD-1 positive cells and (D) expression of CD38/HLA-DR, PD-1 and KI-67 within CD8+ PD-1+ T cells is shown.
Table S5 from Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma
Authors: Tong Kit I. , Yoon Sharon , Isaev Keren , Bakhtiari Mehran , Lackraj Tracy , He Michael Y. , Joynt Jesse , Silva Anjali , Xu Maria C. , Privé Gilbert G. , He Housheng Hansen , Tiedemann Rodger E. , Chavez Elizabeth A. , Chong Lauren C. , Boyle Merrill , Scott David W. , Steidl Christian , Kridel Robert
Published: April 2023

gProfiler results for pathways enriched by ERV-associated genes with significantly upregulated gene expression.
Figure S4 from Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe
Authors: Nie Pengju , Kalidindi Teja , Nagle Veronica L. , Wu Xianzhong , Li Thomas , Liao George P. , Frost Georgia , Henry Kelly E. , Punzalan Blesida , Carter Lukas M. , Lewis Jason S. , Pillarsetty Naga Vara Kishore , Li Yue-Ming
Published: April 2023

Supplementary Figure 4. Representative MR imaging of U87 glioblastoma mouse model (top panel) versus sham control group (bottom panel).
Figure S3 from Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe
Authors: Nie Pengju , Kalidindi Teja , Nagle Veronica L. , Wu Xianzhong , Li Thomas , Liao George P. , Frost Georgia , Henry Kelly E. , Punzalan Blesida , Carter Lukas M. , Lewis Jason S. , Pillarsetty Naga Vara Kishore , Li Yue-Ming
Published: April 2023

Supplementary Figure 3. Representative PET imaging of endogenously developed mammary tumors from MMTVPyMT transgenic mice using [124I]PN67. The tumor location was indicated by red cycles. PET imaging studies were performed at 2h post-injection on a microPET scanner with (bottom panel) or without (top panel) blocking inhibitor (1, 30mg/kg).
Supplementary Table S2 S4 S6 S7 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Authors: Kim Dae-Hwan , Sun Duanchen , Storck William K. , Welker Leng Katherine , Jenkins Chelsea , Coleman Daniel J. , Sampson David , Guan Xiangnan , Kumaraswamy Anbarasu , Rodansky Eva S. , Urrutia Joshua A. , Schwartzman Jacob A. , Zhang Chao , Beltran Himisha , Labrecque Mark P. , Morrissey Colm , Lucas Jared M. , Coleman Ilsa M. , Nelson Peter S. , Corey Eva , Handelman Samuel K. , Sexton Jonathan Z. , Aggarwal Rahul , Abida Wassim , Feng Felix Y. , Small Eric J. , Spratt Daniel E. , Bankhead Armand , Rao Arvind , Gesner Emily M. , Attwell Sarah , Lakhotia Sanjay , Campeau Eric , Yates Joel A. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Table S2 S4 S6 S7 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Supplementary Figure S6 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Authors: Kim Dae-Hwan , Sun Duanchen , Storck William K. , Welker Leng Katherine , Jenkins Chelsea , Coleman Daniel J. , Sampson David , Guan Xiangnan , Kumaraswamy Anbarasu , Rodansky Eva S. , Urrutia Joshua A. , Schwartzman Jacob A. , Zhang Chao , Beltran Himisha , Labrecque Mark P. , Morrissey Colm , Lucas Jared M. , Coleman Ilsa M. , Nelson Peter S. , Corey Eva , Handelman Samuel K. , Sexton Jonathan Z. , Aggarwal Rahul , Abida Wassim , Feng Felix Y. , Small Eric J. , Spratt Daniel E. , Bankhead Armand , Rao Arvind , Gesner Emily M. , Attwell Sarah , Lakhotia Sanjay , Campeau Eric , Yates Joel A. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Figure S6 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Supplementary Figure S3 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Authors: Kim Dae-Hwan , Sun Duanchen , Storck William K. , Welker Leng Katherine , Jenkins Chelsea , Coleman Daniel J. , Sampson David , Guan Xiangnan , Kumaraswamy Anbarasu , Rodansky Eva S. , Urrutia Joshua A. , Schwartzman Jacob A. , Zhang Chao , Beltran Himisha , Labrecque Mark P. , Morrissey Colm , Lucas Jared M. , Coleman Ilsa M. , Nelson Peter S. , Corey Eva , Handelman Samuel K. , Sexton Jonathan Z. , Aggarwal Rahul , Abida Wassim , Feng Felix Y. , Small Eric J. , Spratt Daniel E. , Bankhead Armand , Rao Arvind , Gesner Emily M. , Attwell Sarah , Lakhotia Sanjay , Campeau Eric , Yates Joel A. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Figure S3 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Supplementary Figure S1 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Authors: Kim Dae-Hwan , Sun Duanchen , Storck William K. , Welker Leng Katherine , Jenkins Chelsea , Coleman Daniel J. , Sampson David , Guan Xiangnan , Kumaraswamy Anbarasu , Rodansky Eva S. , Urrutia Joshua A. , Schwartzman Jacob A. , Zhang Chao , Beltran Himisha , Labrecque Mark P. , Morrissey Colm , Lucas Jared M. , Coleman Ilsa M. , Nelson Peter S. , Corey Eva , Handelman Samuel K. , Sexton Jonathan Z. , Aggarwal Rahul , Abida Wassim , Feng Felix Y. , Small Eric J. , Spratt Daniel E. , Bankhead Armand , Rao Arvind , Gesner Emily M. , Attwell Sarah , Lakhotia Sanjay , Campeau Eric , Yates Joel A. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Figure S1 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Supplementary Figure 3 from PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions
Authors: Nimmakayala Rama Krishna , Rauth Sanchita , Chirravuri Venkata Ramakanth , Marimuthu Saravanakumar , Nallasamy Palanisamy , Vengoji Raghupathy , Lele Subodh M. , Rachagani Satyanarayana , Mallya Kavita , Malafa Mokenge P. , Ponnusamy Moorthy P. , Batra Surinder K.
Published: April 2023

Acino-ductal intermediate cells show stemness features.
Supplementary materials-Neutrophil chemotaxis videos from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Authors: Wu Jing , Yuan Ying , Long Priel Debra A. , Fink Danielle , Peer Cody J. , Sissung Tristan M. , Su Yu-Ting , Pang Ying , Yu Guangyang , Butler Madison K. , Mendoza Tito R. , Vera Elizabeth , Ahmad Salman , Bryla Christine , Lindsley Matthew , Grajkowska Ewa , Mentges Kelly , Boris Lisa , Antony Ramya , Garren Nancy , Siegel Christine , Lollo Nicole , Cordova Christine , Aboud Orwa , Theeler Brett J. , Burton Eric M. , Penas-Prado Marta , Leeper Heather , Gonzales Javier , Armstrong Terri S. , Calvo Katherine R. , Figg William D. , Kuhns Douglas B. , Gallin John I. , Gilbert Mark R.
Published: April 2023

Neutrophils chemotaxis video
Supplementary Table-S6 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

Supplementary Table-S6
Supplementary Table-S1 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

Supplementary Table-S1
Supplementary Fig. 7 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

Hierarchical clustering of GC and healthy plasma samples
Supplementary Fig. 3 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

Workflow of model training and test for GI cancer prediction. (a) Initial markers discovery was conducted with 1653 GI cancer and 287 normal tissues. Targeted bisulfite sequencing that covers the initial selected CpG sites was performed on 300 plasma samples, including 254 GI cancer and 46 normal samples. GI plasma samples set was split into training set (70%) and test set (30%). The training set was used for calling differential methylated regions, feature selection and training random forest prediction models. The test set was used for model performance evaluation. (b) Annotations of panGI markers selected from GI cancer tissues.
Supplementary Fig. 15 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

EAC prediction accuracy using various number of DMRs identified from EAC vs. healthy plasma sample analysis
Supplementary Fig. 14 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

GC prediction accuracy using various number of DMRs identified from GC vs. healthy plasma sample analysis
Supplementary Fig 18 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

Multi-class (top) prediction accuracy using GI cancer-specific DMRs
Supplementary Data from Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia
Authors: Spitzer Barbara , Rutherford Kayleigh D. , Gundem Gunes , McGovern Erin M. , Millard Nathan E. , Arango Ossa Juan E. , Cheung Irene Y. , Gao Teng , Levine Max F. , Zhang Yanming , Medina-Martínez Juan S. , Feng Yi , Ptashkin Ryan N. , Bolton Kelly L. , Farnoud Noushin , Zhou Yangyu , Patel Minal A. , Asimomitis Georgios , Cobbs Cassidy C. , Mohibullah Neeman , Huberman Kety H. , Arcilla Maria E. , Kushner Brian H. , Modak Shakeel , Kung Andrew L. , Zehir Ahmet , Levine Ross L. , Armstrong Scott A. , Cheung Nai Kong V. , Papaemmanuil Elli
Published: April 2023

Supplementary Data from Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia
Supplementary Table 2 from Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non–Small Cell Lung Cancer
Authors: Gavrielatou Niki , Liu Yuting , Vathiotis Ioannis , Zugazagoitia Jon , Aung Thazin Nwe , Shafi Saba , Fernandez Aileen , Schalper Kurt , Psyrri Amanda , Rimm David L.
Published: April 2023

Supplemental Table 2. Co-location scores among clinical benefit and LTB subgroups. (LTB: long-term benefit)
Supplementary Table 1 from Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non–Small Cell Lung Cancer
Authors: Gavrielatou Niki , Liu Yuting , Vathiotis Ioannis , Zugazagoitia Jon , Aung Thazin Nwe , Shafi Saba , Fernandez Aileen , Schalper Kurt , Psyrri Amanda , Rimm David L.
Published: April 2023

Supplemental Table 1. Cohort characteristics.
Supplementary Figure 3 from Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non–Small Cell Lung Cancer
Authors: Gavrielatou Niki , Liu Yuting , Vathiotis Ioannis , Zugazagoitia Jon , Aung Thazin Nwe , Shafi Saba , Fernandez Aileen , Schalper Kurt , Psyrri Amanda , Rimm David L.
Published: April 2023

Supplemental Figure 3. PD-L1 in tumor by QIF does not correlate with OS or PFS in 1st line A-B and >1st line C-D of ITx treatment.
Supplementary table 1 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
Authors: Rijnders Maud , Balcioglu Hayri E. , Robbrecht Debbie G.J. , Oostvogels Astrid A.M. , Wijers Rebecca , Aarts Maureen J.B. , Hamberg Paul , van Leenders Geert J.L.H. , Nakauma-González J. Alberto , Voortman Jens , Westgeest Hans M. , Boormans Joost L. , de Wit Ronald , Lolkema Martijn P. , van der Veldt Astrid A.M. , Debets Reno
Published: April 2023

Immune parameters in blood, plasma and tumor tissue from mUC patients with stable disease as best overall response to anti-PD1
Supplementary figure legends from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
Authors: Rijnders Maud , Balcioglu Hayri E. , Robbrecht Debbie G.J. , Oostvogels Astrid A.M. , Wijers Rebecca , Aarts Maureen J.B. , Hamberg Paul , van Leenders Geert J.L.H. , Nakauma-González J. Alberto , Voortman Jens , Westgeest Hans M. , Boormans Joost L. , de Wit Ronald , Lolkema Martijn P. , van der Veldt Astrid A.M. , Debets Reno
Published: April 2023

Legends to supplementary figure 1 - 9
Supplementary figure 6 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
Authors: Rijnders Maud , Balcioglu Hayri E. , Robbrecht Debbie G.J. , Oostvogels Astrid A.M. , Wijers Rebecca , Aarts Maureen J.B. , Hamberg Paul , van Leenders Geert J.L.H. , Nakauma-González J. Alberto , Voortman Jens , Westgeest Hans M. , Boormans Joost L. , de Wit Ronald , Lolkema Martijn P. , van der Veldt Astrid A.M. , Debets Reno
Published: April 2023

Transcriptomic analysis of immune cell fractions, T-cell subsets, and chemo-attractants of baseline metastatic tumor biopsies from mUC patients
Supplementary figure 5 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
Authors: Rijnders Maud , Balcioglu Hayri E. , Robbrecht Debbie G.J. , Oostvogels Astrid A.M. , Wijers Rebecca , Aarts Maureen J.B. , Hamberg Paul , van Leenders Geert J.L.H. , Nakauma-González J. Alberto , Voortman Jens , Westgeest Hans M. , Boormans Joost L. , de Wit Ronald , Lolkema Martijn P. , van der Veldt Astrid A.M. , Debets Reno
Published: April 2023

Correlations between immune parameters in blood, plasma and tumor tissue
Supplementary Data from Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome
Authors: Schwartz Christopher J. , da Silva Edaise M. , Marra Antonio , Gazzo Andrea M. , Selenica Pier , Rai Vikas K. , Mandelker Diana , Pareja Fresia , Misyura Maksym , D'Alfonso Timothy M. , Brogi Edi , Drullinsky Pamela , Razavi Pedram , Robson Mark E. , Drago Joshua Z. , Wen Hannah Y. , Zhang Liying , Weigelt Britta , Shia Jinru , Reis-Filho Jorge S. , Zhang Hong
Published: April 2023

Table S1-S3
Supplementary figure 2 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
Authors: Rijnders Maud , Balcioglu Hayri E. , Robbrecht Debbie G.J. , Oostvogels Astrid A.M. , Wijers Rebecca , Aarts Maureen J.B. , Hamberg Paul , van Leenders Geert J.L.H. , Nakauma-González J. Alberto , Voortman Jens , Westgeest Hans M. , Boormans Joost L. , de Wit Ronald , Lolkema Martijn P. , van der Veldt Astrid A.M. , Debets Reno
Published: April 2023

Numbers of major T-cell subsets in peripheral blood and expression of T-cell maturation/activation markers on CD4+ T-cells
Table S3 from A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors
Authors: Shaikh Fyza Y. , White James R. , Gills Joell J. , Hakozaki Taiki , Richard Corentin , Routy Bertrand , Okuma Yusuke , Usyk Mykhaylo , Pandey Abhishek , Weber Jeffrey S. , Ahn Jiyoung , Lipson Evan J. , Naidoo Jarushka , Pardoll Drew M. , Sears Cynthia L.
Published: April 2023

Table S3